Abstract
Pharmacogenetics could be a useful tool for performing tailored anticancer chemotherapy. Several polymorphisms potentially affecting enzymes responsible for metabolism, transport and mechanism of action of irinotecan, fluoropyrimidines and antifolate agents have been investigated and sometimes associated with toxicity and response. In particular, uridine diphosphoglucuronosyl transferase 1A1 (UGT1A1) enzyme is responsible for detoxification of irinotecan active metabolite, SN38. A polymorphic structure in the promoter region (UGT1A1*28) may affect irinotecan toxicity and SN38 plasma level. Methylenetetrahydrofolate reductase (MTHFR) is a key enzyme in the folate cycle, presenting two common polymorphisms (677C>T and 1298 A>C) which have impact on toxicity and efficacy of methotrexate and 5-fluorouracil.
Original language | English |
---|---|
Pages (from-to) | 31-35 |
Number of pages | 5 |
Journal | Journal of Chemotherapy |
Volume | 16 |
Issue number | SUPPL. 4 |
Publication status | Published - Nov 2004 |
Keywords
- 5-fluorouracil
- Irinotecan
- Methotrexate
- MTHFR
- Pharmacogenetics
- UGT1A1
ASJC Scopus subject areas
- Microbiology (medical)
- Pharmacology (medical)